Erratum to Issaenko OA, et al. Cell Cycle Volume 11, Issue 9; pp. 1804-17

Figures & data

Table 1. Chemical formulas, other known names and known references for chalcone-derivatives.

Table

Compound	R1	R2	P	Reported IC50 (µM) HeLa cells	Alternative nomenclature	Reference
RA-1	Cl	Cl	-CO-Phenylalanine	0.32		1
AM146	H	Cl	CH3	1.5–1.83	RAMB1	2, 3
RA-9	H	NO2	H	2.37	RAMB9	2
RA-14	H	NO2	CH3	2.03	KVI-14, RAMB14	2

Table

Compound	R1	R2	P	Reported IC50 (µM) HeLa cells	Alternative nomenclature	Reference
RA-1	Cl	Cl	-CO-Phenylalanine	0.32		1
AM146	H	Cl	CH3	1.5–1.83	RAMB1	2, 3
RA-9	H	NO2	H	2.37	RAMB9	2
RA-14	H	NO2	CH3	2.03	KVI-14, RAMB14	2

Bazzaro M, Anchoori RK, Mudiam MK, Issaenko O, Kumar S, Karanam B, et al. α,β-Unsaturated carbonyl system of chalcone-based derivatives is responsible for broad inhibition of proteasomal activity and preferential killing of human papilloma virus (HPV) positive cervical cancer cells. J Med Chem 2011; 54:449 - 56; http://dx.doi.org/10.1021/jm100589p; PMID: 21186794

 PubMed Web of Science ®Google Scholar

Issaenko OA, Amerik AY. Chalcone-based small-molecule inhibitors attenuate malignant phenotype via targeting deubiquitinating enzymes. Cell Cycle 2012; 11:1804 - 17; http://dx.doi.org/10.4161/cc.20174; PMID: 22510564

 PubMed Web of Science ®Google Scholar

Anchoori RK, Khan SR, Sueblinvong T, Felthauser A, Iizuka Y, Gavioli R, et al. Stressing the ubiquitin-proteasome system without 20S proteolytic inhibition selectively kills cervical cancer cells. PLoS One 2011; 6:e23888; http://dx.doi.org/10.1371/journal.pone.0023888; PMID: 21909374

 PubMedGoogle Scholar